Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 61 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Follow-Up Questions
Nektar Therapeutics 'in CEO'su kimdir?
Mr. Howard Robin 2007 'den beri şirketle birlikte olan Nektar Therapeutics 'in President 'ıdır.
NKTR hissesinin fiyat performansı nasıl?
NKTR 'in mevcut fiyatı $56.02 'dir, son işlem günde 0% decreased etti.
Nektar Therapeutics için ana iş temaları veya sektörler nelerdir?
Nektar Therapeutics Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Nektar Therapeutics 'in piyasa değerlemesi nedir?
Nektar Therapeutics 'in mevcut piyasa değerlemesi $1.0B 'dir
Nektar Therapeutics al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 9 analist Nektar Therapeutics için analist derecelendirmeleri gerçekleştirdi, bunlar 5 güçlü al, 6 al, 2 tut, 1 sat ve 5 güçlü sat içermektedir
